The present invention relates to a process for preparing gelatin comprising a step of incubating a material comprising collagen with an enzyme composition comprising an acid protease which has at least 70% identity to the amino acid sequence of SEQ ID NO:1, and preparing the gelatin. The invention also relates to gelatin obtained by a process as disclosed herein.

The present invention relates to a process for preparing gelatin comprising a step of incubating a material comprising collagen with an enzyme composition comprising an acid protease which has at least 70% identity to the amino acid sequence of SEQ ID NO:1, and preparing the gelatin. The invention also relates to gelatin obtained by a process as disclosed herein.

The present invention relates to endoproteases. More particularly, the present invention relates to the use of endoproteases for reduction or elimination of beer haze.

The present invention relates to endoproteases. More particularly, the present invention relates to the use of endoproteases for reduction or elimination of beer haze.

The present invention provides compositions and methods for the production and delivery of recombinant double-stranded RNA molecules (dsRNA) encoding heterologous proteins, which can be useful for various therapeutic purposes as well as for the production of desired proteins. The compositions contain engineered double-stranded RNA particles (dsRPs) that can contain a double-stranded RNA molecule that can be a genome or portion of a genome, which can be enclosed in a capsid or coat protein. The dsRNA molecule also comprises an RNA sub-sequence that encodes a heterologous protein. The dsRPs can be derived from wild-type viral organisms. The delivery of the dsRPs (or DNA or RNA molecules) of the invention to an organism provides for therapeutic benefits as well as for the production of desired proteins.

The present invention provides compositions and methods for the production and delivery of recombinant double-stranded RNA molecules (dsRNA) encoding heterologous proteins, which can be useful for various therapeutic purposes as well as for the production of desired proteins. The compositions contain engineered double-stranded RNA particles (dsRPs) that can contain a double-stranded RNA molecule that can be a genome or portion of a genome, which can be enclosed in a capsid or coat protein. The dsRNA molecule also comprises an RNA sub-sequence that encodes a heterologous protein. The dsRPs can be derived from wild-type viral organisms. The delivery of the dsRPs (or DNA or RNA molecules) of the invention to an organism provides for therapeutic benefits as well as for the production of desired proteins.

Provided are an Aspergillus mutant strain which can dramatically enhance production of a heterologous enzyme when a saccharifying enzyme gene is transferred into the strain to perform transformation and a transformant having a saccharifying enzyme gene transferred into the Aspergillus mutant strain. The Aspergillus mutant strain has been completely or partially deficient in three genes of Aspergillus oryzae strain HO2 (accession number: NITE BP-01750): a prtR gene coding for a transcription factor; a pepA gene coding for an extracellular acid protease; and a cpI gene coding for an extracellular acid carboxypeptidase.

Provided are an Aspergillus mutant strain which can dramatically enhance production of a heterologous enzyme when a saccharifying enzyme gene is transferred into the strain to perform transformation and a transformant having a saccharifying enzyme gene transferred into the Aspergillus mutant strain. The Aspergillus mutant strain has been completely or partially deficient in three genes of Aspergillus oryzae strain HO2 (accession number: NITE BP-01750): a prtR gene coding for a transcription factor; a pepA gene coding for an extracellular acid protease; and a cpI gene coding for an extracellular acid carboxypeptidase.

It is an object of the present invention to provide a practical means of producing cysteine from glutathione that is also suitable for use in the field of foods. Cysteine is produced from glutathione by a first step of producing cysteinylglycine by the action of a -glutamyl peptidase derived from a microorganism on reduced glutathione; and a second step of producing cysteine by the action of an acid protease derived from a microorganism on the cysteinylglycine.

It is an object of the present invention to provide a practical means of producing cysteine from glutathione that is also suitable for use in the field of foods. Cysteine is produced from glutathione by a first step of producing cysteinylglycine by the action of a -glutamyl peptidase derived from a microorganism on reduced glutathione; and a second step of producing cysteine by the action of an acid protease derived from a microorganism on the cysteinylglycine.